Amylyx director Cohen proposes $2.95M share sale
The notice also lists Cohen's sale of 30,464 common shares for gross proceeds of $980,503.90 on September 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Joshua Barry Cohen, identified as a director and officer of Amylyx Pharmaceuticals, Inc. (AMLX), gave notice of a proposed sale of 100,000 common shares, with an aggregate market value of $2,950,000 and an approximate sale date of November 9, 2026. The notice lists 128,562,904 common shares outstanding and states that 100,000 common shares were acquired from the issuer as founders shares on January 13, 2014. It lists May 11, 2026 as the plan adoption or instruction date if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.